Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy
- AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system
- Data to be presented at ASGCT 2026 show when used as a monotherapy, AT-108 doubled median survival
- When used in combination with immune checkpoint blockade (ICB), AT-108 demonstrated strong anti-tumor activity, including significantly extending survival and achieving complete tumor regressions
- Findings show AT-108 induces systemic, dose-dependent efficacy with activity across distinct tumor microenvironments, and highlight key biomarker parameters to explore in a future clinical trial
Lund, Sweden, 27 April 2026 – Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces it will present advanced preclinical data on its lead asset AT-108, a first-in-class, off-the-shelf cancer immunotherapy, in an oral presentation at the ASGCT Annual Meeting, held from 11-15 May, 2026, in Boston, Massachusetts, US.
